Found: 195
Select item for more details and to access through your institution.
Ruxolitinib dose management as a key to long-term treatment success.
- Published in:
- 2016
- By:
- Publication type:
- journal article
The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 9, p. 3573, doi. 10.1007/s00277-024-05912-8
- By:
- Publication type:
- Article
Associations Between Global Mental Health and Response to an App-Based Meditation Intervention in Myeloproliferative Neoplasm Patients.
- Published in:
- Integrative Cancer Therapies, 2020, v. 19, p. 1, doi. 10.1177/1534735420927780
- By:
- Publication type:
- Article
Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention: A Qualitative Study.
- Published in:
- Integrative Cancer Therapies, 2018, v. 17, n. 4, p. 1150, doi. 10.1177/1534735418808595
- By:
- Publication type:
- Article
Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research.
- Published in:
- Integrative Cancer Therapies, 2017, v. 16, n. 4, p. 439, doi. 10.1177/1534735416661417
- By:
- Publication type:
- Article
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 6, p. 594, doi. 10.1002/ajh.25777
- By:
- Publication type:
- Article
Facing erythrocytosis: Results of an international physician survey.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 9, p. E225, doi. 10.1002/ajh.25545
- By:
- Publication type:
- Article
Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. E626, doi. 10.1002/ajh.24866
- By:
- Publication type:
- Article
Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 10, p. 864, doi. 10.1002/ajh.24098
- By:
- Publication type:
- Article
Association of the blood eosinophil count with hematological malignancies and mortality.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 3, p. 225, doi. 10.1002/ajh.23916
- By:
- Publication type:
- Article
How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 6, p. 581, doi. 10.1002/ajh.23690
- By:
- Publication type:
- Article
A surprising cause of masses in the chest.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 6, p. 518, doi. 10.1002/ajh.23343
- By:
- Publication type:
- Article
Long-term outcome of pomalidomide therapy in myelofibrosis.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 1, p. 66, doi. 10.1002/ajh.22233
- By:
- Publication type:
- Article
International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 1, p. 96, doi. 10.1002/ajh.21892
- By:
- Publication type:
- Article
Phase1/-2 study of Pomalidomide in myelofibrosis.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 2, p. 129, doi. 10.1002/ajh.21598
- By:
- Publication type:
- Article
Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 5, p. 265, doi. 10.1002/ajh.21391
- By:
- Publication type:
- Article
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
- Published in:
- American Journal of Hematology, 2008, v. 83, n. 5, p. 363, doi. 10.1002/ajh.21149
- By:
- Publication type:
- Article
Images submission: Extramedullary hematopoiesis.
- Published in:
- American Journal of Hematology, 2008, v. 83, n. 2, p. 171, doi. 10.1002/ajh.20978
- By:
- Publication type:
- Article
Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms.
- Published in:
- Molecular Diagnosis & Therapy, 2012, v. 16, n. 5, p. 269, doi. 10.1007/s40291-012-0006-3
- By:
- Publication type:
- Article
Construcción del Derecho de las Audiencias: el Caso de las Defensorías del Televidente en Colombia.
- Published in:
- Law, State & Telecommunications Review / Revista de Direito, Estado e Telecomunicações, 2022, v. 14, n. 1, p. 139, doi. 10.26512/lstr.v14i1.37717
- By:
- Publication type:
- Article
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
- Published in:
- Biologics: Targets & Therapy, 2007, v. 1, n. 2, p. 129
- By:
- Publication type:
- Article
Ironía, parrhesía, cinismo y posverdad como despligues de la intención del discurso.
- Published in:
- Tonos Digital: Revista de Estudios Filológicos, 2021, n. 41, p. 1
- By:
- Publication type:
- Article
Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995.
- Published in:
- American Journal of Hematology, 1999, v. 61, n. 1, p. 10, doi. 10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I
- By:
- Publication type:
- Article
Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge Deficit.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.
- Published in:
- Journal of Experimental Pharmacology, 2016, v. 8, p. 11, doi. 10.2147/JEP.S110702
- By:
- Publication type:
- Article
Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 10, p. 714, doi. 10.1016/j.clml.2023.06.004
- By:
- Publication type:
- Article
MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S364, doi. 10.1016/S2152-2650(21)01836-X
- By:
- Publication type:
- Article
MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S363, doi. 10.1016/S2152-2650(21)01835-8
- By:
- Publication type:
- Article
MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S360, doi. 10.1016/S2152-2650(21)01829-2
- By:
- Publication type:
- Article
MPN-164: Overall Survival (OS) and Progression-Free Survival (PFS) in Patients Treated with Fedratinib as First-Line Myelofibrosis (MF) Therapy and after Prior Ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 Trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S356, doi. 10.1016/S2152-2650(21)01822-X
- By:
- Publication type:
- Article
MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S353, doi. 10.1016/S2152-2650(21)01817-6
- By:
- Publication type:
- Article
Poster: MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S235, doi. 10.1016/S2152-2650(21)01478-6
- By:
- Publication type:
- Article
Poster: MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01456-7
- By:
- Publication type:
- Article
Poster: MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01455-5
- By:
- Publication type:
- Article
Poster: MPN-164: Overall Survival (OS) and Progression-Free Survival (PFS) in Patients Treated with Fedratinib as First-Line Myelofibrosis (MF) Therapy and after Prior Ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 Trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01454-3
- By:
- Publication type:
- Article
Poster: MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01453-1
- By:
- Publication type:
- Article
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S356, doi. 10.1016/j.clml.2019.07.375
- By:
- Publication type:
- Article
Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S355, doi. 10.1016/j.clml.2019.07.374
- By:
- Publication type:
- Article
Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Models to Predict Response to JAK-inhibitor Therapy in Patients with Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S358, doi. 10.1016/j.clml.2017.07.190
- By:
- Publication type:
- Article
Work Productivity Impairment and Symptom Burden among Patients with Myeloproliferative Neoplasms (MPNs): Findings from the Living with MPN Patient Survey.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S355, doi. 10.1016/j.clml.2017.07.184
- By:
- Publication type:
- Article
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Update: a Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S95, doi. 10.1016/j.clml.2016.07.135
- By:
- Publication type:
- Article
Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
- Published in:
- 2015
- By:
- Publication type:
- journal article